A selective growth-hormone secretagogue popular for sleep, recovery, and “healthy aging” — often stacked with CJC-1295. Here’s what it actually does, the appetite catch most people miss, and the IGF-1 and glucose risks the marketing skips.
The one-sentence version: ipamorelin nudges your pituitary to release growth hormone via the ghrelin receptor; it’s popular for sleep/recovery/aging and is usually stacked with CJC-1295, but it’s not FDA-approved, the wellness benefits are weakly evidenced in healthy adults, it can increase appetite, and it carries the same IGF-1 and glucose cautions as other GH-raising compounds.
Ipamorelin is a growth-hormone secretagogue — it prompts the pituitary to release the body’s own growth hormone. Specifically, it’s a ghrelin-receptor agonist (a “GHRP”-type peptide). More GH downstream means more IGF-1, the hormone that carries out many of growth hormone’s effects.
Its main selling point is selectivity: unlike older secretagogues (such as GHRP-6 or GHRP-2), ipamorelin raises GH without meaningfully raising cortisol or prolactin. That’s a real pharmacologic distinction — but “cleaner stimulation of GH” still means raising GH and IGF-1, with the cautions that follow.
Ipamorelin is rarely sold or discussed alone. It’s almost always paired with CJC-1295 (a GHRH analog), because the two raise GH through different, complementary mechanisms. Vendors and clinics market “CJC/Ipa” as a single product.
Worth being clear-eyed about: “CJC-1295 + ipamorelin” is a stack, not a single compound — often sold pre-mixed in one vial. That means you can’t introduce one at a time, can’t isolate which one causes a benefit or a reaction, and you compound the GH-axis effects. Before using a combined product, read the risks of stacking peptides.
Ipamorelin isn’t approved for anything, so all use is off-label. The popular goals:
Better sleep and faster recovery are the most cited reasons people use it, and since GH is released largely during deep sleep, there’s a mechanism. But robust outcome data in otherwise-healthy adults is limited; reports are largely anecdotal.
Raising GH can influence body composition, but whether ipamorelin delivers meaningful, lasting fat-loss or lean-mass benefits in healthy adults — beyond what diet, training, and sleep already do — is not well established.
Because ipamorelin acts on the ghrelin receptor — and ghrelin is the body’s primary hunger signal — it can increase appetite (though generally less than older GHRPs). That’s an important and frequently-overlooked point:
If you’re taking a GLP-1 (semaglutide, tirzepatide, retatrutide) for weight loss and add ipamorelin, you may be pulling appetite in two opposite directions at once — the GLP-1 suppressing hunger and the ghrelin-receptor agonist potentially increasing it. That’s a confusing, uncharacterized combination, and it’s a clinician conversation, not a self-experiment.
Is this “just for bodybuilders”? No — ipamorelin is genuinely dual-use. It’s heavily marketed by anti-aging, longevity, and wellness clinics to ordinary aging adults for sleep, recovery, and body composition, and it’s also used in fitness circles. The compound is identical; only the framing changes. The realistic-expectations, safety-first lens here applies no matter why someone is considering it.
Ipamorelin is a real, relatively “clean” growth-hormone secretagogue, and the selectivity that makes it popular is a genuine pharmacologic feature. But it’s not approved, the sleep/recovery/body-composition benefits people are sold are weakly evidenced in healthy adults, it’s almost always used as a stack (with the added risks that brings), it can increase appetite, and it carries the same IGF-1 and glucose cautions as any GH-raising compound. If you’re considering it, that’s a conversation for a clinician who can screen for contraindications and monitor labs — not a pre-mixed vial from an unverified supplier.
It’s a selective GH secretagogue used off-label — mainly via wellness/anti-aging clinics (often with CJC-1295) — for sleep, recovery, and body composition. Not FDA-approved. The GH-release effect is real; the wellness benefits are weakly evidenced in healthy adults.
Both raise GH but via different receptors: sermorelin is a GHRH analog; ipamorelin is a ghrelin-receptor agonist. Ipamorelin is “selective” (little cortisol/prolactin rise). They’re often combined — which is a stack. See the sermorelin guide.
It can — it acts on the ghrelin (hunger) receptor, though generally less than older GHRPs. Notably relevant if you’re on a GLP-1 for weight loss, since the two affect appetite in opposite directions.
The GH-axis risks (IGF-1/cancer signaling, glucose impairment) plus appetite increase, water retention, headache, and injection-site reactions — compounded by the fact that it’s usually stacked and the gray-market supply is unverified.
No — it’s dual-use, heavily marketed to ordinary aging adults by wellness/longevity clinics as well as used in fitness circles. Same compound, different framing.
This guide is general legal and educational information, not legal or medical advice, and does not create an attorney-client or physician-patient relationship. It is written by a California-licensed attorney, not a physician. Discussion of off-label use is descriptive, not a recommendation. Ipamorelin affects the growth-hormone axis and is not FDA-approved; decisions about it — especially in combination with other compounds or medications — should be made with a licensed clinician who can screen for contraindications (including cancer history and glucose status) and monitor appropriate labs. Research peptides sold “for research use only” are not approved for human use. Verify current information before relying on it. Current as of June 20, 2026.